Management of the patient after heart transplant

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 6, 2004, Pages 459-469

  Mathier, Michael A ^a   McNamara, Dennis M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ATORVASTATIN; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; COLESTYRAMINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; DIURETIC AGENT; GANCICLOVIR; GEMFIBROZIL; INSULIN; LISINOPRIL; METFORMIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG; VALACICLOVIR;

ADRENAL SUPPRESSION; ANEMIA; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIET THERAPY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GRAFT REJECTION; HEART DISEASE; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION PREVENTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIFESTYLE; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MENTAL INSTABILITY; MYALGIA; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE INFECTION; PSYCHOSIS; RESTENOSIS; REVIEW; SKIN DISEASE; SKIN FRAGILITY; THROMBOCYTOPENIA; THRUSH; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 9944259459     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0003-x     Document Type: Review

References (50)

1. Taylor DO, Edwards LB, Mohacsi PJ, et al.: The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official Adult Heart Transplant Report-2003. J Heart Lung Transplant 2003, 22:616-624.
2. International Society tor Heart and Lung Transplant. http:/www.ishlt.org/registries/. Accessed June 1, 2004.
3. Brann WM, Bennett LE, Keck BM, Hosenpud JD: Morbidity, functional status, and immunosuppressive therapy after heart transplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant 1998, 17:374-382.
4. Kobashigawa JA, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
5. Jimenez J, Kapadia SR, Yamani MH, et al.: Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant 2001, 20:393-398.
6. Valantine H: Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004, 23(5 suppl):S187-S193.
7. Subramanian AK, Quinn TC, Kickler TS, et al.: Correlation of chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002, 73:761-764.
8. Schwaiblmair M, von Scheidt W, Uberfuhr P, et al.: Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy. Chest 1999, 116:332-339.
9. Aranda JM, Pauly DF. Kerensky RA, et al.: Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. J Heart Lung Transplant 2002, 21: 60-866.
10. Schnetzler B, Drobinski G, Dorent R, et al.: The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000, 19: 57-565.
11. Cardillo M, Rossini G, Scalamogna M, et al.: Tumor incidence in heart transplant patients: report of the North Italy Transplant Program Registry. Transplant Proc 2001, 33: 840-1843.
12. Fortina AB, Caforio AL, Piaserico S, et al.: Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000, 19:249-255.
13. Jemec GBE, Holm EA: Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003, 75:253-257.
14. Gao SZ, Chaparro SV, Perlroth M, et al.: Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003, 22:505-514.
15. Demers P, Moffatt S, Oyer PE, et al.: Long-term results of heart transplantation in patients older than 60 years. J Thorac Cardiovasc Surg 2003, 126:224-231.
16. Caforio AL, Fortina AB, Piaserico S, et al.: Skin cancer in heart transplant recipients. Circulation 2000, 102(suppl 3):III222-III227.
17. Zilz ND, Olson LJ, McGregor CG: Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001, 20:770-772.
18. Taylor DO, Barr ML, Radovancevic B, et al.: A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999, 18:336-345.
19. Kobashigawa J, Miller L, Relund D, et al.: A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998, 66:507-515.
20. Mancini D, Pinney S, Burkhoff D, et al.: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.
21. Rubin RH: Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000, 19:731-735.
22. Keay S: Cardiac transplantation: pre-transplant infectious diseases evaluation and post-transplant prophylaxis. Curr Infect Dis Rep 2002, 4:285-292.
23. Egan JJ, Carroll KB, Yonan N, et al.: Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant 2002, 21: 60-466.
24. Eisen HJ: Hypertension in heart transplant recipients: more than just cyclosporine. J Am Coll Cardiol 2003, 41: 33-434.
25. Andreassen AK, Hartmann A, Offstad J, et al.: Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol 1997, 29:1324-1331.
26. Brozena SC, Johnson MR, Ventura H, et al.: Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantafion. J Am Coll Cardiol 1996, 27:1707-1712.
27. Lang CC, Beniaminovitz A, Edwards N, Mancini DM: Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 2003, 22:244-249.
28. Marchetti P: New-onset diabetes after transplantation. J Heart Lung Transplant 2004, 23(5 suppl):S194-S201.
29. Davidson J, Wilkinson A, Dantal J, et al.: New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75(suppl ):SS3-S24.
30. Fatemeh A, Jackson CH, Parameshwar J, et al.: Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2003, 73:1258-1264.
31. Pflugfelder PW, Huff M, Oskalns R, et al.: Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995, 14: 13-622.
32. Wenke K, Meiser B, Thiery J, et al.: Simvastatin initiated early after heart transplantation. Circulation 2003, 107:93-97.
33. Keogh A, Macdonald P, Kaan A, et al.: Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000, 19:529-537.
34. Bonet LA, Martinez-Dolz L, Vives MA, et al.: Lipid-lowering effect of atorvastatin in heart transplantation. Transplant Proc 2002, 34:179-181.
35. Weis M, Pehlivanli S, Meiser BM, von Scheidt W: Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001, 38:814-818.
36. Eisen HJ, Tuzcu EM, Dorent R, et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349: 47-858.
37. Doshi AA, Rogers J, Kern MJ, Hauptman PJ: Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. Am J Cardiol 2004, 93:90-92.
38. Grise MA, Reilly JP, Tobis JM, et al.: Intracoronary radiation to treat in-stent restenosis in six cardiac transplant patients. Catheter Cardiovasc Interv 2003, 60:41-44.
39. Ono M, Michler RE: Beating heart coronary artery bypass surgery after orthotopic heart transplantation. J Card Surg 2003, 18:545-549.
40. Aleksic I, Piotrowski JA, Kamler M, et al.: Minimally invasive direct coronary artery bypass in a cardiac transplant recipient with allograft vasculopathy. Ann Thorac Surg 2004, 77:1433-1434.
41. Radovancevic B, McGiffin DC, Kobashigawa JA, et al.: Reptransplantation in 7,290 primary transplant patients: a l0-year multi-institutional study. J Heart Lung Transplant 2003, 22: 62-868.
42. Sehgal V, Radhakrishnan J, Appel GB, et al.: Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids and hypertension. Am J Kidney Dis 1995, 26:193-201.
43. Vossler MR, Ni H, Toy W, Hershberger RE: Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation. J Heart Lung Transplant 2002, 21:874-881.
44. Goldstein DJ, Zuech N, Sehgal V, et al.: Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997, 63:664-668.
45. Van Gelder T, Balk AH, Zietse R, et al.: Survival of heart transplant recipients with cyclosporine-induced renal insufficiency. Transplant Proc 1998, 30:1122-1123.
46. Satchithananda DK, Parameshwar J, Sharples I, et al.: The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience. J Heart Lung Transplant 2002, 21:651-657.
47. Baran DA, Galin ID, Sandler D, et al.: Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. Transplant Proc 2002, 34:1872-1873.
48. Groetzner J, Meiser B, Landwehr P, et al.: Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004, 77:568-574.
49. Snell GI, Levvey BJ, Chin W, et al.: Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002, 21: 40-546.
50. Frimat L, Villemot JP, Cormier L, et al.: Treatment of end-stage renal failure after heart transplantation. Nephrol Dial Transplant 1998, 13:2905-2908.